首页>
外国专利>
Method for predicting the response of NSCLC patients to treatment with an EGFR inhibitor-tk
Method for predicting the response of NSCLC patients to treatment with an EGFR inhibitor-tk
展开▼
机译：预测NSCLC患者对EGFR抑制剂-tk治疗的反应的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method for determining whether a patient who has been diagnosed with lung non-small cell cancer (NSCLC) is a responder to treatment with a receptor inhibitor epidermal growth factor tyrosine kinase (EGFR-TK), comprising: to. obtaining an expression profile of proteins from a tissue sample or lung cells from the patient who has been diagnosed with NSCLC cancer; and b. determining the level of expression in the tissue or cells of the following proteins: p70S6K (SEQ ID No. 17), phospho-S6 (SEQ ID No. 18), phospho-AKT (SEQ ID No. 19), phospho-mTOR (SEQ ID No. 20), phospho-PTEN (SEQ ID No. 21), EGFR (SEQ ID No. 25), phospho-ER (SEQ ID No. 27), phospho-AR (SEQ ID No. 28), AIK (SEQ ID No. 29), osteopontin (SEQ ID No. 30), MMP11 (SEQ ID No. 31), GFAP (SEQ ID No. 32); c. wherein overexpression in tissue of lung cancer or in the cells as compared to expression in normal lung tissue or cells of p70S6K, phospho-S6, phospho-AKT, phospho-mTOR, phospho-PTEN, EGFR, phospho-ER, phospho-AR, AIK, osteopontin, MMP11 and GFAP indicates that the patient responds to treatment with an EGFR-TK.
展开▼
机译：一种确定已被诊断出患有肺非小细胞癌（NSCLC）的患者是否是接受受体抑制剂表皮生长因子酪氨酸激酶（EGFR-TK）治疗的反应者的方法，包括：至。从被诊断患有NSCLC癌症的患者的组织样品或肺细胞中获得蛋白质的表达谱;和b。确定以下蛋白质在组织或细胞中的表达水平：p70S6K（SEQ ID No.17），磷酸S6（SEQ ID No.18），磷酸Akt（SEQ ID No.19），磷酸-mTOR（ SEQ ID No.20），磷酸-PTEN（SEQ ID No.21），EGFR（SEQ ID No.25），磷酸-ER（SEQ ID No.27），磷酸-AR（SEQ ID No.28），AIK （SEQ ID No.29），骨桥蛋白（SEQ ID No.30），MMP11（SEQ ID No.31），GFAP（SEQ ID No.32）; C。其中与正常肺组织或细胞中p70S6K，磷酸-S6，磷酸-AKT，磷酸-mTOR，磷酸-PTEN，EGFR，磷酸-ER，磷酸-AR的表达相比，在肺癌组织或细胞中的过表达， AIK，骨桥蛋白，MMP11和GFAP表示患者对EGFR-TK的治疗有反应。
展开▼
